Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

Autor: R. Coleman Lindsley, Thomas Kielsgaard Kristensen, Mette Brabrand, Mads Thomassen, Charles Laurore, Jesper Stentoft, Christina Ellervik, Ann Mullally, Donna Neuberg, Lukas Frans Ocias, Daniel El Fassi, Karin de Stricker, William Duke, Anwesha Nag, Christopher J. Gibson, Marianne Tang Severinsen, Torben A Kruse, Lillian Werner, Torben Mourits-Andersen, Mikael Frederiksen, Trine Alma Knudsen, Thomas Stauffer Larsen, Aaron R. Thorner, Ulrik Malthe Overgaard, Dennis Lund Hansen, Bruce M. Wollison, Vibe Skov, Lasse Kjær, Joern Starklint, Kristen E. Stevenson, Ole Weis Bjerrum, Hans Carl Hasselbalch

Publikováno v: Knudsen, T A, Skov, V, Stevenson, K E, Werner, L, Duke, W, Laurore, C, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Hansen, D L, Ellervik, C, El Fassi, D, de Stricker, K, Ocias, L F, Brabrand, M, Bjerrum, O W, Overgaard, U, Frederiksen, M, Kristensen, T, Kruse, T, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Stentoft, J, Starklint, J, Neuberg, D, Kjaer, L, Larsen, T S, Hasselbalch, H C, Lindsley, R C & Mullally, A 2022, ' Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses ', Blood Advances, vol. 6, no. 7, pp. 2107-2119 . https://doi.org/10.1182/bloodadvances.2021004856
Knudsen, T A, Skov, V, Stevenson, K E, Werner, L, Duke, W, Laurore, C, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Hansen, D L, Ellervik, C, El Fassi, D, de Stricker, K, Ocias, L F, Brabrand, M, Bjerrum, O W, Overgaard, U M, Frederiksen, M, Kristensen, T K, Kruse, T A, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Stentoft, J, Starklint, J, Neuberg, D S, Kjaer, L, Larsen, T S, Hasselbalch, H C, Lindsley, R C & Mullally, A 2022, ' Genomic Profiling of a Randomized Trial of Interferon-α versus Hydroxyurea in MPN Reveals Mutation-Specific Responses ', Blood advances, vol. 6, no. 7, pp. 2107–2119 . https://doi.org/10.1182/bloodadvances.2021004856
Knudsen, T A, Skov, V, Stevenson, K, Werner, L, Duke, W, Laurore, C, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Hansen, D L, Ellervik, C, Fassi, D E, de Stricker, K, Ocias, L F, Brabrand, M, Bjerrum, O W, Overgaard, U M, Frederiksen, M, Kristensen, T K, Kruse, T A, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Stentoft, J, Starklint, J, Neuberg, D S, Kjaer, L, Larsen, T S, Hasselbalch, H C, Lindsley, R C & Mullally, A 2022, ' Genomic profiling of a randomized trial of interferon-a vs hydroxyurea in MPN reveals mutation-specific responses ', Blood advances, vol. 6, no. 7, pp. 2107-2119 . https://doi.org/10.1182/bloodadvances.2021004856
Knudsen, T A, Skov, V, Stevenson, K, Werner, L, Duke, W, Laurore, C, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Hansen, D L, Ellervik, C, Fassi, D E, de Stricker, K, Ocias, L F, Brabrand, M, Bjerrum, O W, Overgaard, U M, Frederiksen, M, Kristensen, T K, Kruse, T A, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Stentoft, J, Starklint, J, Neuberg, D S, Kjaer, L, Larsen, T S, Hasselbalch, H C, Lindsley, R C & Mullally, A 2022, ' Genomic profiling of a randomized trial of interferon-a vs hydroxyurea in MPN reveals mutation-specific responses ', Blood Advances, vol. 6, no. 7, pp. 2107-2119 . https://doi.org/10.1182/bloodadvances.2021004856

Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a8b3349a821d5426c8d40af43b1de45
https://findresearcher.sdu.dk:8443/ws/files/201081075/Open_Access_Version.pdf

Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1

Autor: Karin de Stricker, Wolfgang Brück, Eleonora Aronica, Felice Giangaspero, Benedicte Parm Ulhøi, Simone Schmid, Annika K. Wefers, Viktoria Ruf, David T.W. Jones, Christel Herold-Mende, Jeanette Krogh Petersen, Daniel Schrimpf, Andreas von Deimling, Henning B. Boldt, Maria Gardberg, David Capper, Karima Mokhtari, Felix Sahm, Philipp Sievers, Romain Appay, Stefan M. Pfister, Dominique Figarella-Branger, Sebastian Brandner, Bjarne Winther Kristensen, Martin Hasselblatt, Elisabeth J. Rushing, Wolfgang Wick, Daniel Hänggi, David E. Reuss, Pieter Wesseling, Annekathrin Reinhardt, Damian Stichel, Benoit Lhermitte, Franck Bielle, Roland Coras

Publikováno v: Sievers, P, Appay, R, Schrimpf, D, Stichel, D, Reuss, D E, Wefers, A K, Reinhardt, A, Coras, R, Ruf, V C, Schmid, S, de Stricker, K, Boldt, H B, Kristensen, B W, Petersen, J K, Ulhøi, B P, Gardberg, M, Aronica, E, Hasselblatt, M, Brück, W, Bielle, F, Mokhtari, K, Lhermitte, B, Wick, W, Herold-Mende, C, Hänggi, D, Brandner, S, Giangaspero, F, Capper, D, Rushing, E, Wesseling, P, Pfister, S M, Figarella-Branger, D, von Deimling, A, Sahm, F & Jones, D T W 2019, ' Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1 ', Acta Neuropathologica, vol. 138, no. 3, pp. 497-504 . https://doi.org/10.1007/s00401-019-02038-4
Acta neuropathologica. Springer Verlag
Acta Neuropathologica, 138(3), 497-504. Springer Verlag

Rosette-forming glioneuronal tumor (RGNT) is a rare brain neoplasm that primarily affects young adults. Although alterations affecting the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathway have been associ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0ab0d7f5eec9657ea5ed00f5c715f09
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068114873&origin=inward

Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in

Autor: Eric, Santoni-Rugiu, Linea C, Melchior, Edyta M, Urbanska, Jan N, Jakobsen, Karin de, Stricker, Morten, Grauslund, Jens B, Sørensen

Publikováno v: Cancers

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and result in increased sensitivity to EGFR-tyrosine-kinase-inhibitors (EGFR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bcefa284343af925d5d7310891e6e230
https://pubmed.ncbi.nlm.nih.gov/31266248

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Autor: Mads Thomassen, Jesper Stentoft, Hans Carl Hasselbalch, Thomas Stauffer Larsen, Ole Weis Bjerrum, Marianne Tang Severinsen, Mette Brabrand, Vibe Skov, Lukas Frans Ocias, Thomas Kielsgaard Kristensen, Torben Mourits-Andersen, Ulrik Malthe Overgaard, Mikael Frederiksen, Trine Alma Knudsen, Dennis Lund Hansen, Torben A Kruse, Lasse Kjær, Peter Møller, Daniel El Fassi, Jørn Starklint, Karin de Stricker

Publikováno v: Knudsen, T A, Hansen, D L, Ocias, L F, Bjerrum, O W, Brabrand, M, El Fassi, D, Frederiksen, M, Kjaer, L, Kristensen, T K, Kruse, T A, Mourits-Andersen, T, Moller, P, Overgaard, U M, Severinsen, M T, Skov, V, Stentoft, J, Starklint, J, de Stricker, K, Thomassen, M, Larsen, T S & Hasselbalch, H C 2018, ' Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial-a Randomized Controlled Phase III Clinical Trial ', Blood, vol. 132, no. 1 . https://doi.org/10.1182/blood-2018-99-111255
Knudsen, T A, Hansen, D L, Ocias, L F, Bjerrum, O W, Brabrand, M, El Fassi, D, Frederiksen, M, Kjær, L, Kristensen, T K, Kruse, T A, Mourits-Andersen, T, Møller, P, Overgaard, U M, Severinsen, M T, Skov, V, Stentoft, J, Starklint, J, de Stricker, K, Thomassen, M, Larsen, T S & Hasselbalch, H C 2018, ' Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera : Preliminary Results from the Three-Year Analysis of the Daliah Trial-a Randomized Controlled Phase III Clinical Trial ', Blood, vol. 132, no. Suppl 1, pp. 580 . https://doi.org/10.1182/blood-2018-99-111255

Background Recombinant Interferon Alpha-2a (r-IFNα) is a potent immunomodulating agent, which has been used off-label for the treatment of polycythemia vera (PV) for more than three decades and has been demonstrated to induce high rates of clinical,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd40781d5cd616e581043ece0f569001
https://portal.findresearcher.sdu.dk/da/publications/e3179d20-b94b-4c83-9ed2-31301298e4e6

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Autor: Hans Carl Hasselbalch, Mikael Frederiksen, Trine Alma Knudsen, Thomas Kielsgaard Kristensen, Lukas Frans Ocias, Ann Mullally, Bruce M. Wollison, Christina Ellervik, Ole Weis Bjerrum, Donna Neuberg, Torben A Kruse, Torben Mourits-Andersen, Karin de Stricker, Thomas Stauffer Larsen, Anwesha Nag, Aaron R. Thorner, Mads Thomassen, Mette Brabrand, Vibe Skov, Joern Starklint, Lillian Werner, Peter Møller, Daniel El Fassi, Jesper Stentoft, Christopher J. Gibson, R. Coleman Lindsley, William Duke, Ulrik Malthe Overgaard, Dennis Lund Hansen, Marianne Tang Severinsen, Lasse Kjær

Publikováno v: Knudsen, T A, Skov, V, Werner, L, Duke, W, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Lund Hansen, D, Larsen, T S, Ellervik, C, El Fassi, D, de Stricker, K, Ocias, L F, Brabrand, M, Weiss Bjerrum, O, Overgaard, U M, Frederiksen, M, Kielsgaard Kristensen, T, Kruse, T A, Thomassen, M, Mourits-Andersen, H T, Severinsen, M T, Jesper, S, Starklint, J, Møller, P, Neuberg, D S, Kjær, L, Hasselbalch, H C, Coleman Lindsley, R & Mullally, A 2019, ' Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response ', Blood, vol. 134, no. Supplement 1, 4202 . https://doi.org/10.1182/blood-2019-126164
Knudsen, T A, Skov, V, Werner, L, Duke, W, Gibson, C J, Nag, A, Thorner, A R, Wollison, B, Lund Hansen, D, Larsen, T S, Ellervik, C, El Fassi, D, de Stricker, K, Ocias, L F, Brabrand, M, Weiss Bjerrum, O, Overgaard, U M, Frederiksen, M, Kielsgaard Kristensen, T, Kruse, T A, Thomassen, M, Mourits-Andersen, T, Severinsen, M T, Jesper, S, Starklint, J, Møller, P, Neuberg, D S, Kjær, L, Hasselbalch, H C, Coleman Lindsley, R & Mullally, A 2019, ' Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response ', American Society of Hematology: 61st Annual Meeting (ASH), Orlando, United States, 07/12/2019-10/12/2019 . < https://ashpublications.org/blood/article/134/Supplement_1/4202/425637/Genomic-Profiling-of-a-Phase-III-Clinical-Trial-of >

Background: To investigate the role of genomics in determining response and resistance to front line treatment in MPN, we performed somatic mutational profiling of the DALIAH trial, a randomized controlled phase III trial of interferon versus hydroxy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::086d55fe777b2ddaceac2b76923d6e4d
https://doi.org/10.1182/blood-2019-126164